 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
6 News |  |
- Grippol / NPO Petrovax, Polyoxidonium (azoximer bromide) / NPO Petrovax
Effect of Influenza Immunization With Inactivated Trivalent Polymer-subunit Vaccine in Lung Transplant Recipients (Walter E. Washington Convention Center, Area F, Hall C (Lower Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_7444;
Patients received immunosuppressive therapy, that included calcineurin inhibitors, antimetabolites (mycophenolate mofetil), and systemic glucocorticosteroids.For vaccination, an inactivated polymer-subunit vaccine "Grippol@plus" (Petrovax Pharm LLC) was used, which contains in one dose (0.5 ml) hemagglutinins of 3 strains of the influenza virus in amount of 5 ?g of each hemagglutinin and 500 ?g of the immunoadjuvant azoximer bromide. Influenza vaccination of lung transplant recipients with inactivated polymer-subunit vaccine with reduced amount of antigens is safe and induces high levels of seroprotection.
- || Grippol / NPO Petrovax, Polyoxidonium (azoximer bromide) / NPO Petrovax
Clinical, Journal: Low-dose influenza vaccine Grippol Quadrivalent with adjuvant Polyoxidonium induces a T helper-2 mediated humoral immune response and increases NK cell activity. (Pubmed Central) - Apr 28, 2021
Polyoxidonium without AGs also induced expression of ICOSL, which plays an important role in T-dependent humoral immune response. In summary, the low-dose influenza vaccine GQ with Polyoxidonium adjuvant is immunogenic, induces a Th2-polarized T-cell response and CD4 memory T cells maturation, activates the production of antibodies to influenza hemagglutinins, and increases the activity of NK cells.
- | Grippol / NPO Petrovax
Clinical, Journal: Structural Analysis of Peripheral Organs of the Immune System in the Assessment of Grippol Vaccine Safety. (Pubmed Central) - Dec 20, 2019
The structural morphological dynamics of lymphoid tissue under these conditions is shown. Because of the use of the vaccine, the lymphocytopoietic processes in the body are activated, which indicates the formation of an immune response.
- | Grippol / NPO Petrovax
New P2/3 trial: Safety, Reactogenicity, Immunogenicity, and Efficacy of Quadrivalent Inactivated Subunit Influenza Vaccine Grippol® Quadri and Trivalent Inactivated Polymer-Subunit Vaccine Grippol® Plus in Volunteers (clinicaltrials.gov) - Feb 21, 2019
P2/3, N=609, Completed, Sponsor: NPO Petrovax